UniQure pauses dosing in Fabry disease trial amid safety concerns
Administration in the mid-to-high dose cohorts of the gene therapy trial will pause pending further evaluation.
Cytiva Navigating cell therapy WP 4
Lilly stops development of three drugs, including gene therapy
Affinia receives FDA approval for Phase I/II trial for dilated cardiomyopathy
Ultragenyx’s gene therapy shows sustained improvements in MPS IIIA
FDA puts REGENXBIO gene therapy trials on hold after brain tumour
Intellia Therapeutics to resume dosing of gene therapy in Phase III trial
Genespire to take rare disease gene therapy to clinic in 2026
ImmunityBio’s allogeneic CD19 cell therapy shows complete response beyond 15 months
